GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-03-06: Form 6-K; Period of report 2025-03-06; Description TRANSACTION IN OWN SHARES; Document a5448z.htm.
- 2025-03-05: Form 6-K; Period of report 2025-03-05; Description TRANSACTION IN OWN SHARES; Document a3594z.htm.
- 2025-03-04: Form 6-K; Period of report 2025-03-04; Description TRANSACTION IN OWN SHARES; Document a1814z.htm.
- 2025-03-03: Form 6-K; Period of report 2025-03-03; Description GSK PLC 2024 ANNUAL REPORT ON FORM 20-F; Document a1658z.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2025-03-06 | 6-K | 2025-03-06 | TRANSACTION IN OWN SHARES | a5448z.htm |
| 2025-03-05 | 6-K | 2025-03-05 | TRANSACTION IN OWN SHARES | a3594z.htm |
| 2025-03-04 | 6-K | 2025-03-04 | TRANSACTION IN OWN SHARES | a1814z.htm |
| 2025-03-03 | 6-K | 2025-03-03 | GSK PLC 2024 ANNUAL REPORT ON FORM 20-F | a1658z.htm |
| 2025-03-03 | 6-K | 2025-03-03 | TOTAL VOTING RIGHTS | a1448z.htm |
| 2025-03-03 | 6-K | 2025-03-03 | US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS | a0169z.htm |
| 2025-03-03 | 6-K | 2025-03-03 | ANCHOR RESULTS PRESENTED AT 2025 AAAAI | a9964y.htm |
| 2025-03-03 | 6-K | 2025-03-03 | TRANSACTION IN OWN SHARES | a9770y.htm |
| 2025-02-28 | 6-K | 2025-02-28 | TRANSACTION IN OWN SHARES | a7917y.htm |
| 2025-02-27 | 6-K | 2025-02-27 | TRANSACTION IN OWN SHARES | a6885y.htm |
| 2025-02-27 | 6-K | 2025-02-27 | GSK PUBLISHES ANNUAL REPORT 2024 | a7145y.htm |
| 2025-02-26 | 6-K | 2025-02-26 | DIRECTOR/PDMR SHAREHOLDING | a5870y.htm |
| 2025-02-26 | 6-K | 2025-02-26 | TRANSACTION IN OWN SHARES | a4494y.htm |
| 2025-02-25 | 6-K | 2025-02-25 | TRANSACTION IN OWN SHARES | a2797y.htm |
| 2025-02-24 | 6-K | 2025-02-24 | GSK COMPLETES ACQUISITION OF IDRX, INC. | a1769y.htm |
| 2025-02-24 | 6-K | 2025-02-24 | GSK PLC COMMENCES SHARE BUYBACK PROGRAMME | a1771y.htm |
| 2025-02-21 | 6-K | 2025-02-21 | DIRECTORATE CHANGE | a9370x.htm |
| 2025-02-21 | 6-K | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING | a9392x.htm |
| 2025-02-21 | 6-K | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING | a9207x.htm |
| 2025-02-21 | 6-K | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING | a9199x.htm |
| 2025-02-21 | 6-K | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING | a9192x.htm |
| 2025-02-21 | 6-K | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING | a9162x.htm |
| 2025-02-21 | 6-K | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING | a9158x.htm |
| 2025-02-20 | 6-K | 2025-02-20 | NUCALA COPD SUBMISSION ACCEPTED IN CHINA | a7773x.htm |
| 2025-02-18 | 6-K | 2025-02-18 | GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA | a2616x.htm |
| 2025-02-13 | 6-K | 2025-02-13 | DIRECTOR/PDMR SHAREHOLDING | a0565x.htm |
| 2025-02-11 | 6-K | 2025-02-11 | DIRECTOR/PDMR SHAREHOLDING | a7333w.htm |
| 2025-02-05 | 6-K | 2025-02-05 | FINAL RESULTS | finalresults05-0225.htm |
| 2025-02-03 | 6-K | 2025-02-03 | TOTAL VOTING RIGHTS | a7257v.htm |
| 2025-01-28 | 6-K | 2025-01-28 | DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN | a8491u.htm |
| 2025-01-28 | 6-K | 2025-01-28 | EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB | a8408u-gskemaacceptstwosu.htm |
| 2025-01-27 | 6-K | 2025-01-27 | EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION | a7635u.htm |
| 2025-01-21 | 6-K | 2025-01-21 | JEMPERLI EXPANDED APPROVAL IN THE EU | a9254t.htm |
| 2025-01-16 | 6-K | 2025-01-16 | DIRECTOR/PDMR SHAREHOLDING | a6320t.htm |
| 2025-01-15 | 6-K | 2025-01-15 | DIRECTOR/PDMR SHAREHOLDING | a4773t.htm |
| 2025-01-14 | 6-K | 2025-01-14 | DIRECTOR/PDMR SHAREHOLDING | a2991t.htm |
| 2025-01-13 | 6-K | 2025-01-13 | DIRECTOR/PDMR SHAREHOLDING | a1282t.htm |
| 2025-01-13 | 6-K | 2025-01-13 | GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. | a0538t.htm |
| 2025-01-10 | 6-K | 2024-01-10 | SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW | a8269s.htm |
| 2025-01-07 | 6-K | 2024-01-07 | GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION | a3166s.htm |
| 2025-01-03 | 6-K | 2025-01-03 | GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP | a9784r.htm |
| 2025-01-02 | 6-K | 2025-01-02 | TOTAL VOTING RIGHTS | a9718r.htm |